The Only Monthly Membership With a Positive ROI!
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
The Only Monthly Membership With a Positive ROI!
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Comments
Close menu
Loading...
Arcellx
ACLX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$69.38
2.92
4.39%
At Close: -
$68.37
-1.01
-1.46%
After Hours: 4:06 PM EDT
15 minutes delayed
Get Report
Comment
Arcellx (ACLX) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Arcellx (NASDAQ:ACLX) Stock
Arcellx Stock (NASDAQ: ACLX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, August 09, 2024
Arcellx shares are trading higher after the c...
Benzinga Newsdesk
Assessing Arcellx: Insights From 7 Financial Analysts
Benzinga Insights
Needham Reiterates Buy on Arcellx, Maintains ...
Benzinga Newsdesk
Thursday, August 08, 2024
Arcellx Q2 EPS $(0.51) Beats $(0.55) Estimate...
Benzinga Newsdesk
Wednesday, July 24, 2024
Alkermes Lags Q2 Earnings Estimates
Zacks
Monday, July 22, 2024
Decoding 8 Analyst Evaluations For Arcellx
Benzinga Insights
Canaccord Genuity Maintains Buy on Arcellx, M...
Benzinga Newsdesk
Tuesday, June 18, 2024
The Latest Analyst Ratings For Arcellx
Benzinga Insights
Truist Securities Maintains Buy on Arcellx, M...
Benzinga Newsdesk
Friday, May 31, 2024
Expert Ratings For Arcellx
Benzinga Insights
Piper Sandler Initiates Coverage On Arcellx w...
Benzinga Newsdesk
Wednesday, May 15, 2024
Stifel Maintains Buy on Arcellx, Raises Price...
Benzinga Newsdesk
Tuesday, May 14, 2024
Analyst Expectations For Arcellx's Future
Benzinga Insights
Evercore ISI Group Initiates Coverage On Arce...
Benzinga Newsdesk
Monday, May 13, 2024
HC Wainwright & Co. Maintains Buy on Arcellx,...
Benzinga Newsdesk
Friday, May 10, 2024
Needham Reiterates Buy on Arcellx, Maintains ...
Benzinga Newsdesk
Arcellx shares are trading lower after the co...
Benzinga Newsdesk
Thursday, May 09, 2024
Arcellx shares are trading higher after the c...
Benzinga Newsdesk
Arcellx Q1 EPS $(0.14) Beats $(0.51) Estimate...
Benzinga Newsdesk
Tuesday, May 07, 2024
Needham Reiterates Buy on Arcellx, Maintains ...
Benzinga Newsdesk
Monday, April 15, 2024
Peering Into Arcellx's Recent Short Interest
Benzinga Insights
Thursday, April 11, 2024
Needham Reiterates Buy on Arcellx, Maintains ...
Benzinga Newsdesk
Monday, March 18, 2024
Needham Maintains Buy on Arcellx, Raises Pric...
Benzinga Newsdesk
Thursday, March 14, 2024
Stifel Reiterates Buy on Arcellx, Maintains $...
Benzinga Newsdesk
Thursday, March 07, 2024
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Vandana Singh
Morgan Stanley Initiates Coverage On Arcellx ...
Benzinga Newsdesk
Tuesday, March 05, 2024
Truist Securities Maintains Buy on Arcellx, R...
Benzinga Newsdesk
Thursday, February 29, 2024
HC Wainwright & Co. Maintains Buy on Arcellx,...
Benzinga Newsdesk
On Wednesday February 28, 2024, Arcellx Reported Q4 EPS $0.42 Up From $(0.76) YoY, Sales $63.15M
Happy Mohamed
Canaccord Genuity Maintains Buy on Arcellx, R...
Benzinga Newsdesk
Barclays Maintains Overweight on Arcellx, Rai...
Benzinga Newsdesk
Arcellx Analysts Boost Their Forecasts After Q4 Results
Avi Kapoor
Needham Maintains Buy on Arcellx, Raises Pric...
Benzinga Newsdesk
Baird Maintains Outperform on Arcellx, Raises...
Benzinga Newsdesk
Wednesday, February 28, 2024
As Of December 31, 2023, Arcellx Had Cash, Ca...
Benzinga Newsdesk
Thursday, January 04, 2024
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Vandana Singh
Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know
Benzinga Insights
Needham Maintains Buy on Arcellx, Raises Pric...
Benzinga Newsdesk
Tuesday, December 19, 2023
Arcellx shares are trading higher after Scoti...
Benzinga Newsdesk
Scotiabank Initiates Coverage On Arcellx with...
Benzinga Newsdesk
Tuesday, December 12, 2023
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
Needham Reiterates Buy on Arcellx, Maintains ...
Benzinga Newsdesk
Monday, December 11, 2023
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
Vandana Singh
Where Arcellx Stands With Analysts
Benzinga Insights
Needham Maintains Buy on Arcellx, Raises Pric...
Benzinga Newsdesk
Friday, December 08, 2023
Arcellx Announces Continued Robust Long-Term ...
Benzinga Newsdesk
Wednesday, November 15, 2023
HC Wainwright & Co. Maintains Buy on Arcellx,...
Benzinga Newsdesk
Needham Maintains Buy on Arcellx, Raises Pric...
Benzinga Newsdesk
Kite, A Gilead Company, And Arcellx Have Expa...
Benzinga Newsdesk
Monday, November 13, 2023
Arcellx Q3 EPS $(0.81) Misses $(0.65) Estimat...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch